SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Mountain climbing route to peak. Business journey path in progress to peak of success. Climbing road to top. Vector illustration
Psychedelics
Compass’ Psychedelic Shows Durability ‘In Spades’ as Path to FDA Clears
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the requested 12, the company is delivering “in spades,” he said.
February 17, 2026
 · 
3 min read
 · 
Heather McKenzie
3d human colon cross section with waste in the intestine isolated on green background. check colon health, constipation concept, 3d illustration render
Vaccines
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
Competing with giants like Takeda and Moderna, the plucky biotech believes it has unlocked a future with an easy, yearly oral vaccine.
February 17, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Scanner on blue human eye
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to determine a regulatory path for Axpaxli.
February 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
Johns Hopkins’ Thomas Hartung discusses how drug discovery and development will change under evolving regulatory policies that embrace AI technology as well as organoid and other non-animal models of human biology.
February 17, 2026
 · 
1 min read
 · 
Jef Akst
row of medicine ampoules with orange caps close-up
Opinion
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
February 17, 2026
 · 
5 min read
 · 
Tom Kutrubes
stethoscope on glass globe - Usa
FDA
Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push
The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA Medicines. Meanwhile, streamlined communications with regulators in other countries pave the way for rapid uptake of novel modalities.
February 17, 2026
 · 
5 min read
 · 
Heather McKenzie
Water faucet with drop coming out
Manufacturing
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
February 17, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Job Trends
2025 Q4 Job Market Report: Positive Signs Emerge for Job Seekers
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
February 16, 2026
 · 
4 min read
 · 
Angela Gabriel
A bottle of a vaccine on a reflective surface with the illuminated red outline of the world map in red - 3D render
Vaccines
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait
After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.
February 16, 2026
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS